Charles Schwab Investment Management Inc. Has $221,000 Holdings in Cabaletta Bio, Inc. $CABA

Charles Schwab Investment Management Inc. raised its position in Cabaletta Bio, Inc. (NASDAQ:CABA) by 46.3% in the first quarter, according to its most recent disclosure with the SEC. The firm owned 159,866 shares of the company’s stock after acquiring an additional 50,606 shares during the period. Charles Schwab Investment Management Inc. owned approximately 0.32% of Cabaletta Bio worth $221,000 as of its most recent filing with the SEC.

Other hedge funds have also recently added to or reduced their stakes in the company. Federated Hermes Inc. grew its stake in Cabaletta Bio by 133.1% in the first quarter. Federated Hermes Inc. now owns 343,411 shares of the company’s stock valued at $476,000 after acquiring an additional 196,064 shares during the period. Two Sigma Advisers LP grew its stake in Cabaletta Bio by 195.8% in the fourth quarter. Two Sigma Advisers LP now owns 831,900 shares of the company’s stock valued at $1,888,000 after acquiring an additional 550,700 shares during the period. Two Sigma Investments LP grew its stake in Cabaletta Bio by 78.8% in the fourth quarter. Two Sigma Investments LP now owns 751,894 shares of the company’s stock valued at $1,707,000 after acquiring an additional 331,417 shares during the period. Point72 Asset Management L.P. grew its stake in Cabaletta Bio by 89.7% in the fourth quarter. Point72 Asset Management L.P. now owns 1,265,882 shares of the company’s stock valued at $2,874,000 after acquiring an additional 598,607 shares during the period. Finally, Raiffeisen Bank International AG acquired a new stake in Cabaletta Bio in the fourth quarter valued at approximately $493,000.

Cabaletta Bio Trading Down 1.9%

Shares of CABA opened at $1.54 on Friday. The company has a market capitalization of $140.85 million, a price-to-earnings ratio of -0.57 and a beta of 2.86. The stock has a 50 day moving average of $1.57 and a 200 day moving average of $1.61. Cabaletta Bio, Inc. has a 12 month low of $0.99 and a 12 month high of $5.46.

Cabaletta Bio (NASDAQ:CABA) last issued its quarterly earnings results on Thursday, August 7th. The company reported ($0.73) EPS for the quarter, missing analysts’ consensus estimates of ($0.71) by ($0.02). As a group, equities research analysts predict that Cabaletta Bio, Inc. will post -2.34 earnings per share for the current year.

Wall Street Analyst Weigh In

A number of research firms have recently weighed in on CABA. HC Wainwright restated a “buy” rating and issued a $25.00 target price on shares of Cabaletta Bio in a report on Wednesday, June 11th. Citigroup dropped their target price on Cabaletta Bio from $17.00 to $13.00 and set a “buy” rating on the stock in a report on Friday, May 16th. Finally, Guggenheim raised their target price on Cabaletta Bio from $23.00 to $25.00 and gave the company a “buy” rating in a report on Thursday, May 15th. One equities research analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating and one has issued a Hold rating to the stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Buy” and a consensus target price of $14.43.

About Cabaletta Bio

Cabaletta Bio, Inc, a clinical-stage biotechnology company, focuses on the discovery and development of engineered T cell therapies for patients with B cell-mediated autoimmune diseases. The company's lead product candidate is CABA-201, a fully human anti-CD19 binder for the treatment of Phase 1/2 clinical trials in dermatomyositis, anti-synthetase syndrome, immune-mediated necrotizing myopathy, lupus nephritis, non-renal systemic lupus erythematosus, systemic sclerosis, and generalized myasthenia gravis.